Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $128.18

Merck & Co., Inc. (NYSE:MRK) has earned a consensus rating of “Moderate Buy” from the nineteen research firms that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $128.1765.

MRK has been the subject of several recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Merck & Co., Inc. in a research note on Friday, May 1st. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. UBS Group increased their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts and market commentary highlighted that Keytruda drove Merck’s strong first-quarter sales, with revenue topping expectations and sales around $8 billion, reinforcing the drug’s importance to MRK’s 2026 growth outlook. Article Title
• Positive Sentiment: Merck said it will present new long-term oncology data and more than 100 abstracts at ASCO 2026, which could keep investor focus on the strength of its cancer portfolio and pipeline. Article Title
• Positive Sentiment: Merck broadened KEYTRUDA collaboration efforts with partners including Erasca and Inhibrx, signaling continued pipeline development around combination therapies as the company prepares for eventual patent-expiry pressure. Article Title
• Neutral Sentiment: One analyst reinstated Merck with a “Neutral” rating and a $125 price target, suggesting the stock may be fairly valued near current levels rather than clearly undervalued or overvalued. Article Title
• Neutral Sentiment: A valuation-focused article noted mixed recent share performance, including short-term weakness despite strong longer-term returns, which may be tempering enthusiasm even as fundamentals remain solid. Article Title

Merck & Co., Inc. Price Performance

Shares of MRK opened at $113.57 on Friday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The company has a market capitalization of $280.49 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 2.53 and a beta of 0.18. The firm has a 50-day simple moving average of $116.31 and a 200-day simple moving average of $109.01. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the firm earned $2.22 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds have recently added to or reduced their stakes in the company. Dickmeyer Boyce Financial Management Inc. acquired a new stake in Merck & Co., Inc. in the first quarter valued at about $1,111,000. Gibbs Wealth Management lifted its position in Merck & Co., Inc. by 147.2% in the first quarter. Gibbs Wealth Management now owns 12,506 shares of the company’s stock valued at $1,504,000 after purchasing an additional 7,447 shares during the period. Sei Investments Co. lifted its position in Merck & Co., Inc. by 13.9% in the first quarter. Sei Investments Co. now owns 2,102,456 shares of the company’s stock valued at $252,892,000 after purchasing an additional 256,265 shares during the period. Davis R M Inc. lifted its position in Merck & Co., Inc. by 1.3% in the first quarter. Davis R M Inc. now owns 24,395 shares of the company’s stock valued at $2,950,000 after purchasing an additional 302 shares during the period. Finally, GSG Advisors LLC acquired a new stake in Merck & Co., Inc. in the first quarter valued at about $230,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.